Vietnam Approves Biomerica’s EZ Detect™ for Nationwide Distribution

Vietnam Approves Biomerica’s EZ Detect™ for Nationwide Distribution Approval Marks Biomerica’s Strategic Entry into Southeast Asia’s Rapidly Growing Healthcare MarketSimple, FDA-Cleared At-Home Test Detects an Early Warning Sign of Colorectal Cancer in Minutes IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, announced that Vietnam’s Hanoi Department of Health has officially approved the EZ Detect™ colorectal disease at-home screening test for sales and distribution throughout Vietnam. Biomerica is workin...

Biomerica Reports Second Quarter Fiscal 2026 Financial Results

Biomerica Reports Second Quarter Fiscal 2026 Financial Results Operating Expenses Decline 4% Year-to-DateBalance Sheet Strengthens and Working Capital Improves by 14.7% IRVINE, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the second quarter of fiscal 2026 ended November 30, 2025. Key Highlights:  1.Biomerica Expands Commercialization of inFoods® IBS Through Collaboration with Henry Schein     During the second quarter, Biomerica ente...

Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test

Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test CMS is the single largest payer for healthcare in the United States, with Medicare responsible for approximately 21% of total healthcare expenditure.The $300 rate will apply to claims approved and paid by Medicare with dates of service on or after January 1, 2026.Adults of Medicare age comprise over 20% of US adults and a substantial portion of patients with IBS symptoms, making Medicare a critical payer for inFoods® IBS. IRVINE, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMR...

PBSV: Steady as she goes

BCLI: KOL Event Gives Overview of the use of NurOwn® in Alzheimer’s Disease; Raising Valuation to $25/Share...

MNOV: FDA Gives OK to Initiate Clinical Trial of MN-166 to Prevent ARDS in COVID- 19 Patients...